Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Leukemia & lymphoma

Volumn 52, Issue 12, 2011, Pages 2299-2303

  Eleftherakis Papapiakovou, Evangelos ^a   Kastritis, Esftathios ^b   Roussou, Maria ^b   Gkotzamanidou, Maria ^b   Grapsa, Irini ^b   Psimenou, Erasmia ^b   Nikitas, Nikitas ^b   Terpos, Evangelos ^b   Dimopoulos, Meletios A ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DRUG DERIVATIVE; LENALIDOMIDE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; RENAL INSUFFICIENCY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84858795823     PISSN: None     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.597906     Document Type: Article

References (0)